石药集团SYS6088三特异性抗体(PD-1/VEGFA/CTLA-4)获NMPA中国临床试验批准，仅为早期IND阶段、短期无业绩影响

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no
responsibility for the contents of this announcement, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in
reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT
SYS6088 INJECTION (A TRI-SPECIFIC ANTIBODY) OBTAINS
CLINICAL TRIAL APPROVAL IN CHINA
The Board of Directors (the ‘‘Board’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company’’,
together with its subsidiaries, the ‘‘Group’’) is pleased to announce that SYS6088 Injection (the
‘‘Product’’) developed by the Group has obtained approval from the National Medical Products
Administration of the People’s Republic of China to conduct clinical trials in China.
The Product is a recombinant humanised trispecific antibody targeting programmed cell death protein 1
(‘‘PD-1’’), vascular endothelial growth factor A (‘‘VEGFA’’) and cytotoxic T-lymphocyte-associated
antigen 4 (‘‘CTLA-4’’). It can specifically bind to PD-1 and CTLA-4 on the surface of T cell
membranes and to VEGFA in the tumour microenvironment, thereby restoring the killing function of T
lymphocytes (T cells) and inhibiting angiogenesis in the tumour microenvironment, as well as
promoting the activation and expansion of T cells during the immune priming phase, exerting a triple
synergistic anti-tumour effect. Fc engineering reduces the toxicity risk of the Product and effectively
prolongs its half-life.
The indication for the approved clinical trial is advanced or metastatic solid tumours. Preclinical
studies showed that the Product had broad-spectrum anti-tumour potential and demonstrated significant
anti-tumour activity in various malignant tumour models and a favourable safety profile, indicating
high clinical development value.
By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman
Hong Kong, 15 October 2026

–1–

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI
Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr.
CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo,
Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen
and Ms. LI Quan as Independent Non-executive Directors.

–2–